Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 11, 2012 | clinicaltrials |
| NCT00570999 | Palifermin After Haploidentical PBSCT(KGF Haplo Allo) | withdrawn | Phase 2 | 0 | European Society for Blood and Marrow TransplantationNETWORK | 1 | May 10, 2012 |
| clinicaltrials |
| NCT00343447 | Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00003929 | Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2012 | clinicaltrials |
| NCT00005969 | Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 20, 2012 | clinicaltrials |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | withdrawn | Phase 2 | 0 | CABYCINDUSTRY | 1 | Dec 30, 2011 | clinicaltrials |
| NCT01011998 | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | withdrawn | Phase 2 | 0 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 27, 2011 | clinicaltrials |
| NCT00712062 | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | Sep 20, 2011 | clinicaltrials |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | withdrawn | Phase 2 | 37 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | — | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT00149032 | Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host | withdrawn | Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Apr 8, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00162500 | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies | withdrawn | Phase 2 | 15 | Hadassah Medical OrganizationOTHER | 1 | Nov 10, 2010 | clinicaltrials |
| NCT00298467 | MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | withdrawn | Phase 2 | 45 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 26, 2010 | clinicaltrials |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 25 | Cylene PharmaceuticalsINDUSTRY | 1 | Nov 5, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 / Phase 2 | 30 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
Data updated 23 days agoSource updated May 11, 2012source: clinicaltrials